Profile data is unavailable for this security.
About the company
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
- Revenue in USD (TTM)839.36k
- Net income in USD-6.14m
- Incorporated1987
- Employees13.00
- LocationSoligenix IncSUITE C-10, 29 EMMONS DRIVEPRINCETON 08540United StatesUSA
- Phone+1 (609) 538-8200
- Fax+1 (609) 452-6467
- Websitehttps://www.soligenix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calidi Biotherapeutics Inc | 0.00 | -28.74m | 5.74m | 38.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.0241 | 0.00 | -- | -- | 0.00 | -284.51 | -- | -- | -- | -- | -- | -- | -- | -- | -25.25 | 1.25 | -- | -89.98 | -- | -132.57 | -- | -- | -- |
| Goldenwell Biotech Inc | 2.34k | -116.90k | 5.80m | -- | -- | 68.48 | -- | 2,479.23 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -10.77m | 5.81m | 2.00 | -- | -- | -- | -- | -5.98 | -5.98 | 0.00 | -0.0157 | 0.00 | -- | -- | 0.00 | -179.36 | -220.94 | -316.27 | -329.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| HST Global Inc | 0.00 | -146.22k | 5.83m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| SYBLEU Inc | 11.70k | -307.88k | 5.86m | -- | -- | -- | -- | 500.84 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.29m | 5.86m | 4.00 | -- | 0.5737 | -- | 651.18 | -3.76 | -3.76 | 0.0064 | 7.53 | 0.0006 | 0.4291 | -- | 2,250.00 | -35.36 | -110.00 | -40.34 | -- | 60.00 | 65.82 | -58,739.67 | -7,961.14 | 27.64 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Soligenix Inc | 839.36k | -6.14m | 5.91m | 13.00 | -- | 1.71 | -- | 7.04 | -0.9164 | -0.9164 | 0.1085 | 0.243 | 0.0697 | -- | 5.86 | 64,566.15 | -51.01 | -75.40 | -872.23 | -154.32 | 11.59 | 22.83 | -731.60 | -620.02 | -- | -1,677.11 | 0.5639 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Healthy Extracts Inc | 2.49m | -2.47m | 5.93m | -- | -- | 6.19 | -- | 2.38 | -0.8588 | -0.8588 | 0.8611 | 0.3231 | 0.918 | 0.4921 | 36.50 | -- | -91.32 | -53.78 | -174.02 | -146.65 | 65.90 | 45.68 | -99.48 | -87.53 | 0.1636 | -9.72 | 0.5245 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 5.95m | 96.00 | 0.856 | 0.1413 | 1.08 | 0.2017 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Scorpius Holdings Inc | 2.23m | -46.05m | 6.09m | 77.00 | -- | 0.1215 | -- | 2.73 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 6.13m | 9.00 | -- | 0.2897 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.12m | 6.14m | 13.00 | -- | 0.5542 | -- | -- | -8.72 | -8.72 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -154.40 | -84.35 | -175.45 | -90.03 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Protagenic Therapeutics Inc | 0.00 | -5.00m | 6.14m | -- | -- | 1.67 | -- | -- | -1.15 | -1.15 | 0.00 | 0.8271 | 0.00 | -- | -- | -- | -80.91 | -74.49 | -94.48 | -92.56 | -- | -- | -- | -- | -- | -9.56 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| CV Sciences Inc | 16.00m | 3.10m | 6.15m | 42.00 | 1.83 | 2.10 | 1.84 | 0.384 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Soligenix Inc's reporting currency: US Dollar USD
3.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 92.79k | 0.88% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 80.65k | 0.77% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 50.87k | 0.48% |
| Geode Capital Management LLCas of 31 Dec 2023 | 50.20k | 0.48% |
| First Wilshire Securities Management, Inc.as of 31 Dec 2023 | 23.33k | 0.22% |
| Warberg Asset Management LLCas of 31 Dec 2023 | 20.00k | 0.19% |
| Citadel Securities LLCas of 31 Dec 2023 | 17.74k | 0.17% |
| FNY Capital Management LPas of 31 Dec 2023 | 15.00k | 0.14% |
| Two Sigma Investments LPas of 31 Dec 2023 | 11.73k | 0.11% |
| Tower Research Capital LLCas of 31 Dec 2023 | 6.78k | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
